Researchers find new Alzheimer's disease treatment promising

Jul 12, 2009

Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer's disease. The two investigators, Giulio Maria Pasinetti, M.D., Ph.D. , and Hillel Grossman, M.D., presented Phase IIA preliminary clinical findings at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna on Sunday, July 12.

NIC5-15's potential to preserve will be further evaluated in a Phase IIB clinical trial. Early evidence suggests that NIC5-15 is a safe and tolerable natural compound that may reduce the progression of Alzheimer's disease-related dementia by preventing the formation of beta-amyloid plaque, a waxy substance that accumulates between and impacts cognitive function. .

"With affecting 5.2 million Americans, another 5 million with early-state disease, and nearly a half million new cases reported annually, treatments like NIC5-15 would make a significant difference in the lives of many Alzheimer's patients," said Dr. Pasinetti, Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine. "We are hopeful that the follow up clinical study will support this preliminary evidence."

"There are no FDA-approved Alzheimer's disease modifying drugs available today," said Dr. Hillel Grossman, Assistant Professor of Psychiatry, Co-Director of the Clinical Research Core of the Alzheimer's Disease Research Center, and Clinical Director of the Mount Sinai Memory and Aging Center. "Current drugs approved for use help maintain cognitive function, but only for a limited time. NIC5-15 is part of a new class of we found to have the potential of precluding the generation of β-amyloid and, eventually, attenuating cognitive deterioration in preclinical models of Alzheimer's disease."

Source: The Mount Sinai Hospital

Explore further: Syria hit by flesh-eating maggot disease

add to favorites email to friend print save as pdf

Related Stories

Study finds certain drugs cut Alzheimer's

Dec 06, 2006

U.S. scientists say they've identified anti-hypertensive agents that can prevent cognitive decline and amyloid neuropathology in Alzheimer patients.

Does growth hormone drug slow Alzheimer's disease?

Nov 17, 2008

A new study shows that a drug that increases the release of growth hormone failed to slow the rate of progression of Alzheimer's disease in humans. The new research is published in the November 18, 2008, print issue of Neurology, the me ...

Recommended for you

Syria hit by flesh-eating maggot disease

11 hours ago

Three cases of myiasis have been reported near Damascus, marking the first appearance of the flesh-eating maggot disease in Syria, UN health experts said Friday.

Sperm can carry Ebola for 82 days: WHO

13 hours ago

Sperm can carry the Ebola virus for at least 82 days, the World Health Organization said Friday, urging men recovering from the disease to use condoms for three months after the onset of symptoms.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Birger
not rated yet Jul 13, 2009
"NIC5-15 is part of a new class of natural compounds we found to have the potential of precluding the generation of %u03B2-amyloid"

-This article is not very helpful. What other natural compounds? Is this referring to the effect of substances like coffe (discussed earlier at Physorg.com), or something else?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.